NASDAQ:SCLXW Scilex (SCLXW) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free SCLXW Stock Alerts $0.24 +0.01 (+4.35%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$0.15▼$0.2450-Day Range$0.21▼$0.4552-Week Range$0.15▼$2.15Volume1,580 shsAverage Volume7,895 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestSocial Media Get Scilex alerts: Email Address Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About ScilexScilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Read More SCLXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCLXW Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive SCLXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolNASDAQ:SCLXW CUSIPN/A CIK1820190 Webwww.scilexholding.com Phone650 516 4310FaxN/AEmployees105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$46.74 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Henry H. Ji Ph.D. (Age 60)Executive Chairman Comp: $885.43kMr. Stephen Ma (Age 51)Senior VP, CFO & Corporate Secretary Comp: $708.78kMr. Jaisim Shah (Age 64)President, CEO & Director Comp: $785.73kDr. Suketu D. Desai Ph.D. (Age 58)CTO & Senior VP Ms. Gigi DeGuzmanExecutive Director of Administrative Operations & Head of Human ResourcesMr. Steven F. Lincoln J.D.General Counsel & Chief Compliance OfficerMr. Sumant RajendranExecutive Director of MarketingMike CiaffiNational Sales DirectorMr. Suresh K. Khemani (Age 64)Senior VP & Chief Commercial Officer Comp: $456.82kDr. Dmitri V. Lissin M.D. (Age 64)Senior VP & Chief Medical Officer Comp: $528.83kMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All Competitors SCLXW Stock Analysis - Frequently Asked Questions How have SCLXW shares performed in 2024? Scilex's stock was trading at $0.36 on January 1st, 2024. Since then, SCLXW stock has decreased by 33.4% and is now trading at $0.2399. View the best growth stocks for 2024 here. How do I buy shares of Scilex? Shares of SCLXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCLXW) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & CompanyBiden Nomination CANCELED?The Freeport SocietyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media348 million Americans lives to END as we know it?The Oxford ClubA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.